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The role of topoisomerase IIβ was investigated in cell lines exposed to two DNA damaging agents, ionising radiation (IR)
or etoposide, a drug which acts on topoisomerase II. The appearance and resolution of γH2AX foci in murine embryonic
fibroblast cell lines, wild type and null for DNA topoisomerase IIβ, was measured after exposure to ionising radiation (IR) or
etoposide. Topoisomerase II-DNA adduct levels were also measured. IR rapidly triggered phosphorylation of histone H2AX,
less phosphorylation was seen in TOP2β−/− cells, but the difference was not statistically significant. IR did not produce
topoisomerase II-DNA adducts above control levels. Etoposide triggered the formation of topoisomerase II-DNA adducts and
the phosphorylation of histone H2AX, the γH2AX foci appeared more slowly with etoposide than with IR. Topoisomerase II-DNA
complexes inWT cells but not TOP2β−/− cells increased significantly at 24 hours with the proteasome inhibitor MG132, suggesting
topoisomerase IIβ adducts are removed by the proteasome.
1. Introduction
Exogenous agents such as ionising radiation (IR) and
ultraviolet light or endogenous agents such as free radicals
produced within cells can damage the DNA of eukaryotic
organisms. Diverse mechanisms have evolved to detect and
repair DNA damage that threatens the integrity of the
genome. Here, we study two DNA damaging agents used in
the treatment of cancer, IR and the epipodophyllotoxin drug
etoposide that acts on topoisomerase II.
Cellular DNA damage responses to IR exposure have
been extensively investigated and several pathways exist
within the cell to respond to double strand breaks (DSBs)
induced by ionising radiation (IR). Histone H2AX is rapidly
phosphorylated following IR, with foci observed within the
first minute following exposure [1–3]. The phosphoryla-
tion of H2AX occurs over megabase regions of chromatin
extending away from the site of DNA damage [1] and
initiates assembly of several proteins involved in the DNA
damage response [4]. H2AX phosphorylation has been
shown to be essential for correct amplification of the DNA
damage response [5–7]. At sublethal levels of DNA damage,
phosphorylated H2AX (termed γH2AX) forms distinct foci
within the cell nuclei. At less than 150DSBs per nucleus,
there exists a 1 : 1 relationship of γH2AX foci : DSBs [2].
At these levels of DNA damage, γH2AX can be used as
an accurate and sensitive surrogate reporter of DNA DSB
levels [8]. H2AX can also be phosphorylated in response to
topoisomerase II-targeting agents [9–12].
Topoisomerase II is an enzyme that alters the topological
state of DNA via a transient covalent enzyme-bridged
double strand break in the DNA, through which a second
DNA helix can pass. These protein associated breaks can
be stabilised by drugs such as etoposide [13, 14]. Two
isoforms of topoisomerase II exist, termed α and β [15],
these are both targeted by etoposide [16–18]. The genotoxic
effects of etoposide are generally considered to be mediated
through conversion of stabilised protein-DNA complexes to
protein free “frank” DSBs [19, 20], possibly via collisions
between the drug-stabilised topoisomerase-DNA complex
and RNA polymerase during transcription or with DNA
replication forks, analogous to the situation seen with
topoisomerase I [21, 22]. Frank DSBs may also be generated
by proteolytic degradation of the topoisomerase II moiety
2 Journal of Nucleic Acids
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Figure 1: Effect of topoisomerase IIβ status on γH2AX focus formation in response to IR. WT and TOP2β−/− MEFs were exposed to 1Gy
IR (a) or 2Gy IR (b) and γH2AX foci were counted at 20 minutes, 2 hours, 5 hours, and 24 hours after exposure. Data are derived from at
least n = 3 independent experiments.
[23–26] and topoisomerase IIβ is thought to be preferentially
degraded over the α isoform [26]. A reduction in etoposide
induced DSB levels was reported in cells cotreated with
the proteasome inhibitor MG-132 [26], suggesting that the
proteasome has a role in converting etoposide-stabilised
protein-DNA complexes into frank DSBs [26]. Additionally
a 5′ tyrosyl DNA phosphodiesterase (TTRAP) has recently
been identified that may play a role in generating frank DSBs
ready for repair [27].
Topoisomerase II has been implicated in the cellular
response to DNA DSBs. Down regulating topoisomerase IIα
by siRNA altered the response to radiation [28] whilst topoi-
somerase IIβ has been reported to play a role in promoting
DSB repair following peroxide damage [29]. The damage
sensor TopBP1 was first identified as a topoisomerase IIβ
interacting protein [30], and WSTF (Williams syndrome
transcription factor) which regulates the H2AX DNA dam-
age response [7] interacts with WINAC, a topoisomerase IIβ
containing multi protein complex [31]. Thus topoisomerase
IIβ may be directly involved in damage detection and
signalling following IR via protein-protein interactions.
Alternatively, topoisomerase IIβ may be required for proper
regulation of genes involved in the damage responses. For
example, cells downregulated for topoisomerase IIβ have
been reported to express reduced peroxiredoxin 2 [32].
To investigate whether topoisomerase IIβ affects the cellular
response to IR or etoposide induced DNA damage, we
used WT and TOP2β−/− MEFs, we used H2AX assays and
in parallel the trapped in agarose DNA immunostaining
(TARDIS) assay to examine the kinetics of formation and
removal of topoisomerase II-DNA complexes in response to
IR or etoposide treatment.
2. Materials and Methods
2.1. Cell Culture. Wild-type mTOP2β-4 (containing both
topoisomerase IIα and topoisomerase IIβ) [WT] and
mtop2β-5 [TOP2β−/−] immortalized mouse embryonic
fibroblasts (MEFs) have been described previously [17] and
were maintained as monolayers in Dulbecco’s Modified
Eagle’s Medium (DMEM) supplemented with 10% foetal
bovine serum (FBS) and penicillin (50 µg/mL)/streptomycin
(50 µg/mL). Cells were grown at 37◦C in a humidified
atmosphere containing 5% CO2. Cell culture reagents were
obtained from Gibco BRL (Paisley, UK).
2.2. Chemicals and DNA Damaging Agents. All chemicals
were obtained from Sigma-Aldrich (Poole, UK) and VWR
International (Lutterworth, UK). Etoposide was obtained
Journal of Nucleic Acids 3
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Figure 2: γH2AX foci formed in response to increasing doses of
etoposide. WT and TOP2β−/− MEFs were exposed to 0.1, 1, 10,
and 100 µM etoposide for 2 hours and then assayed for γH2AX
foci. (a) Histograms of foci number ± SEM at each dose counted.
100 µM was not counted as foci were not distinct at this dose. Data
derived from one experiment. (b) Representative images of γH2AX
foci (red) in nuclei stained with DAPI (blue) in WT and TOP2β−/−
MEFs.
from Sigma and was dissolved in methanol. IR exposure was
carried out using a Gammacell 1000 irradiator with a [137Cs]
source (Nordion International, Inc.) and was delivered at a
rate of approximately 3.08Gy/min.
2.3. H2AX Focus Assay. The γH2AX focus assay was per-
formed as described previously in detail by Watters and
colleagues [12].
2.4. TARDIS (Trapped in Agarose DNA Immunostaining).
WT and TOP2β−/− MEFs were seeded at 3 × 104 cells/well
into 6-well tissue culture plates and grown to approximately
80% confluency. Cells were exposed to the appropriate
DNA damaging agent (IR or etoposide) and harvested by
trypsinisation at specific time-points as detailed in the text.
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Figure 3: γH2AX foci following a 2 hour short-term exposure
to etoposide. WT and TOP2β−/− MEFs were exposed to 1 µM
etoposide and γH2AX foci were counted at the indicated time
points after drug removal. The data are derived from at least n = 3
independent experiments, each data point shows the mean ± SEM.
Trypsinised cells were resuspended in 1mL of ice-cold PBS,
centrifuged at 1000 rpm for 3 minutes and then resuspended
in 50 µL of ice-cold PBS. The slide preparation has been
described in detail previously [17]. Slides were probed with
an antibody that detects topoisomerase IIα and β.
Quantification of complex levels has been described
previously [16]. Statistical analyses were carried out using
Graphpad Prism 4 software (Cherwell Scientific, Oxford,
UK.). Two-tailed, paired, and unpaired Students t-tests were
generally used to compare data sets and data sets between cell
lines; analysis of variance (ANOVA) was used for multiple
comparisons where appropriate, as detailed in the text. All
statistical analyses were calculated using a 95% confidence
interval (P < .05).
3. Results and Discussion
The present study examined two DNA damaging agents, IR
and etoposide. γH2AX formation was used as a surrogate
marker for DSBs in parallel with topoisomerase II-DNA
complex measurement in both wild-type and topoisomerase
IIβ null murine embryo fibroblast cell lines (MEFs).
The response to three doses of IR (0.5, 1 and 2Gy)
was determined in MEFs wild type (WT) or null for
topoisomerase IIβ (TOP2β−/−). In response to 1Gy, γH2AX
4 Journal of Nucleic Acids
0
10
20
30
40
50
60
70
80
90
100
N
u
m
b
er
o
f
fo
ci
p
er
n
u
cl
eu
s
C
o
n
tr
o
l
2
0
m
in
s
1
h
r
2
h
rs
5
h
rs
8
h
rs
24
h
rs
Time-point
WT
β−/−
Figure 4: γH2AX foci during continuous exposure to etoposide
up to 24 hours. WT and TOP2β−/− MEFs were exposed to 1 µM
etoposide and γH2AX foci were counted at the indicated time
points up to 24 hours. The data are derived from at least n = 3
independent experiments, each data point shows the mean ± SEM.
focus numbers were similar between the two cell lines, with
∼35 γH2AX foci per nucleus at 20 minutes (Figure 1(a)).
γH2AX foci were most abundant at the 20 minute time-
point after irradiation and decreased at each subsequent
time-point investigated and returned to background levels at
24 hours (Figure 1(a)). Following 2Gy (Figure 1(b)), focus
numbers appeared higher in the WT cell line than the
TOP2β−/− at 20 minutes, 2 hours, and 5 hours following
exposure. The lower foci number in the TOP2β−/− cells
suggests the initial DNA damage responses following IR
are altered in these cells, however, the differences were not
statistically significant by two way ANOVA or Students t-test.
Nor was there any significant difference between the levels
of apoptosis following IR between the two cell lines. The
trapped in agarose DNA immunostaining (TARDIS) assay
was used to detect topoisomerase II protein-DNA complex
levels in these cell lines following IR. Topoisomerase II
complex formation did not increase in response to IR in WT
or TOP2β−/− cells when compared to the untreated cells, as
previously reported for CEM cells [18] (data not shown),
thus IR had no effect upon topoisomerase II-DNA complex
levels in the 24 hours following exposure to 2Gy.
In an etoposide “dose finding” experiment topoiso-
merase IIβ wild-type and null MEF cell lines were exposed
to 0, 0.1, 1, 10, or 100 µM etoposide for 2 hours, after
which time cells were placed in drug-free media for 20
minutes before being assayed for γH2AX foci. Foci numbers
per nucleus increased in both cell lines with increasing
dose of drug. At 100 µM, foci were no longer distinct and
therefore uncountable (Figure 2). To ensure foci were within
a countable range, subsequent experiments were performed
using doses of 1 µM and 10 µM only.
WT and TOP2β−/− cells were exposed to 1.0 µM etopo-
side for 2 hours, cells were then resuspended in drug-
free media and assayed for γH2AX at different time points
after drug removal, 20 minutes, 2 hours, 5 hours, and 24
hours following removal of drug (Figure 3). The kinetics
of focus formation and removal were comparable between
the wild-type and TOP2β−/− cell lines, and by 24 hours
postdrug removal foci numbers were similar to untreated
controls. No statistically significant difference was found
in focus numbers between the two cell lines, indicating
that topoisomerase IIβ status did not affect the kinetics
of disappearance of γH2AX phosphorylation following a 2
hour exposure to 1 µM etoposide, this is consistent with
the evidence that the cytotoxic effect of etoposide is mainly
mediated via topoisomerase IIα in these cells, since the IC50
for etoposide did not differ significantly between the two
cell lines [17]. The topoisomerase II-DNA adducts levels
measured by TARDIS after a 2 hour exposure to etoposide
has previously been reported [17].
Wild-type and TOP2β−/− cells were also exposed con-
tinuously to 1.0 µM etoposide over the course of 24 hours,
and samples removed to quantify γH2AX foci formation at
various time points (Figure 4). After two hours of etoposide
exposure the foci numbers were comparable to that seen after
the two-hour short term exposure, numbers then increased
further with continued exposure to etoposide. The maximal
foci numbers were seen after 8 hours of etoposide, and
they then decreased by 24 hours even though etoposide was
still present. The focus numbers were statistically different
between the two cell lines only at the 24 hours point
(P < .05), when the WT cell line had approximately double
the number of foci compared to the TOP2β−/− cell line.
Topoisomerase II-DNA complex levels in WT and
TOP2β−/− cells were determined using the TARDIS assay
at time-points over a 24 hour continuous exposure to
etoposide at 1 µM (Figure 5(a)) or 10 µM (Figure 5(b)). At
both drug doses and in both cell lines, treatment induced
a time-dependent increase in topoisomerase II DNA adduct
levels (FITC immunofluorescence) up to the 8 hour time-
point followed by a decrease at the 24 hour time-point
(Figures 5(a) and 5(b)). With 1 µM etoposide, the increase
was significant at 8 hours in WT cells and at both 5 hours
(P < .05) and 8 hours (P < .01) in TOP2β−/− cells. Although
levels decreased at 24 hours, immunofluorescence was still
significantly greater than background levels in both wild-
type and TOP2β−/− cells (P < .05). When cells were exposed
to 10 µM etoposide, immunofluorescence levels in WT cells
became statistically significant at 2 hours after drug addition
(P < .05) and remained elevated at all other time-points (P <
.01). In TOP2β−/− cells, levels were significant at 1 hour (P <
.01), 5 hours (P < .05), and 24 hours (P < .001). Notably
immunofluorescence levels were greater in the TOP2β−/−
Journal of Nucleic Acids 5
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Figure 5: TARDIS analysis of cells treated with etoposide continuously for 24 hours. Topoisomerase II-DNA adducts were detected using an
antibody that detects both isoforms in WT and TOP2β−/− MEFs following exposure to 1 µM (a) or 10 µM (b). Plots show the mean of the
median FITC fluorescence from at least three independent experiments.
cells than the wild-type cells (Figure 5) at both drug doses
and all time-points (all P-values <.05). The higher complex
levels seen in cells lacking topoisomerase IIβmay result from
the longer half life of topoisomerase IIα complexes [16] or
be due to a role of topoisomerase IIβ in sensing and/or
promoting repair [29] or alternatively to downregulation of
peroxiredoxins in TOP2β−/− cells [32, 33].
To investigate whether the decrease in topoisomerase II-
DNA complexes between the 8 hour and 24 hour time-points
was due to proteasomal degradation of topoisomerase II,
WT and TOP2β−/− cells were incubated in the presence of
the proteasome inhibitor, MG-132, for 30 minutes prior to
and during 24 hour exposures to 1 µM and 10 µM etoposide.
As shown in Figure 6(e), when treated with MG-132 alone,
topoisomerase II-DNA complex levels were only significantly
elevated above background levels at the 24 hour time-point.
Immunofluorescence levels were comparable in the WT
and TOP2β−/− cells at all time-points considered. In cells
cotreated with etoposide and MG-132, topoisomerase II-
DNA complex levels did not decrease between the 8 hour and
24 hour time-points, as seen in cells treated with etoposide
alone. Figure 6(a)–6(d), demonstrate that cotreatment led to
increased immunofluorescence at the 24 hour time-point,
in both cell lines and at both drug doses. This increase was
most dramatic in WT cells, where cotreatment led to a 6-fold
increase in immunofluorescence in cells treated with 1 µM
etoposide and a 15-fold increase in cells treated with 10 µM
etoposide. In the TOP2β−/− cells, the increase was roughly 2-
fold at both doses of drug. This indicates that topoisomerase
II removal at 24 hours is mediated via the proteasome, and
that the effect is greatest on topoisomerase IIβ, in agreement
with previous studies [23, 25, 26].
4. Conclusions
In response to IR phosphorylation of histone H2AX was
triggered immediately, and slightly less phosphorylation was
seen in TOP2β−/− cells, which may indicate altered DNA
damage sensing. As previously reported, IR did not produce
topoisomerase II-DNA adducts. In response to etoposide
both γH2AX foci and topoisomerase II-DNA adducts were
formed, with foci appearing 1 hour after treatment in WT
cells and after 2 hours in TOP2β−/− cells. This was slower
than following treatment with IR, and presumably reflects
the need to remove the topoisomerase II adduct to produce
a frank DSB to trigger phosphorylation of histone H2AX. In
both instances, levels become maximal at the 8 hour time-
point and subsequently decrease at 24 hours.
6 Journal of Nucleic Acids
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Figure 6: Continued.
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Figure 6: TARDIS analysis of cells treated with etoposide continuously for 24 hours plus and minus MG132 or with MG132 alone.
Topoisomerase II-DNA adducts were quantified using an antibody that detects both isoforms. WT MEFs following exposure to 1 µM ±
2 µMMG132 (a), Top2β−/− MEFs following exposure to 1 µM ± 2 µMMG132 (b), WT MEFs following exposure to 10 µM ± 2 µMMG132
(c), Top2β−/−MEFs following exposure to 10 µM± 2 µMMG132 (d), orWT and TOP2β−/−MEFs following exposure to 2 µMMG132 alone
(e). Plots show the mean of the median FITC fluorescence.
Topoisomerase II complexes in WT cells but not
TOP2β−/− cells increased significantly at 24 hours when the
proteasome was inhibited, suggesting that topoisomerase IIβ
adducts are removed by the proteasome.
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